Table 3 Diabetic retinopathy outcomes at Month 12 (M12) and Month 24 (M24) for the treatment-naïve and non-treatment-naïve cohort.

From: Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes

  

Treatment-naïve

Non-treatment-naïve

  

M12 (N = 388)

M24 (N = 326)

M12 (N = 169)

M24 (N = 135)

  

BL n (%)

M12 n (%)

BL n (%)

M24 n (%)

BL n (%)

M12 n (%)

BL n (%)

M24 n (%)

English

R0

3 (1.2)

-

3 (1.2)

4 (1.7)

1 (0.9)

2 (1.9)

1 (0.9)

3 (2.8)

R1

94 (38.7)

98 (40.3)

94 (39.0)

95 (39.4)

37 (34.9)

33 (31.1)

37 (34.9)

37 (34.9)

R2

78 (32.1)

61 (25.1)

78 (32.4)

50 (20.7)

35 (33.0)

30 (28.3)

35 (33.0)

27 (25.5)

R3

41 (16.9)

38 (15.6)

41 (17.0)

46 (19.1)

18 (17.0)

20 (18.9)

18 (17.0)

17 (16.0)

Missing

27 (11.1)

46 (18.9)

25 (10.4)

46 (19.1)

15 (14.2)

21 (19.8)

15 (14.2)

22 (20.8)

Scottish

R0

-

1 (2.2)

-

-

-

-

-

-

R1

21 (45.7)

26 (56.5)

21 (43.8)

28 (58.3)

4 (30.8)

8 (61.5)

4 (28.6)

6 (42.9)

R2

19 (41.3)

10 (21.7)

19 (39.6)

10 (20.8)

5 (38.5)

2 (15.4)

5 (35.7)

3 (21.4)

R3

3 (6.5)

5 (10.9)

3 (6.3)

7 (14.6)

4 (30.8)

2 (15.4)

4 (28.6)

4 (28.6)

R4

-

1 (2.2)

-

-

-

1 (7.7)

-

-

Missing

3 (6.5)

3 (6.5)

5 (10.4)

3 (6.3)

-

-

1 (7.1)

1 (7.1)

  1. Outcomes are provided based on the English National Screening Committee (English) or Scottish Diabetic Retinopathy Grading Scheme (Scottish) classifications as appropriate.
  2. English scale, R0 No visible retinopathy, R1 Background retinopathy, R2 Pre-proliferative retinopathy, R3 Proliferative retinopathy.
  3. Scottish; R0 No visible retinopathy, R1 Mild retinopathy, R2 Observable retinopathy, R3 Referable retinopathy, R4 Proliferative retinopathy.
Back to article page